Novo Nordisk may receive more favorable terms in Medicare program — STAT News

Novo Nordisk may receive more favorable terms than expected in the Medicare Bridge pilot program, which provides coverage for obesity drugs for older adults. STAT News reports.

Coverage of obesity drugs

According to the outlet, Novo Nordisk and Eli Lilly are already receiving significant benefits from the Donald Trump administration’s pilot program. It provides coverage for obesity drugs for elderly patients at a price of $245 per month.

Other pharmaceutical sector news

Roche reported positive results from a phase two study of enisepatide, previously known as CT-388, involving patients with type 2 diabetes and obesity. According to the company, the drug helped reduce body weight and blood sugar levels. Roche is already conducting two phase three weight-loss studies and plans to begin another pivotal trial next year focused on blood sugar control and cardiovascular outcomes.

More current news is available on the UA.News Telegram channel Telegram.

Celldex Therapeutics said its experimental treatment for chronic urticaria met its goals in two phase three studies. Ionis Pharma reported that ulefnersen prolonged survival and slowed the progression of a rare form of amyotrophic lateral sclerosis in a phase three study. The RNA-based drug is licensed to the Japanese pharmaceutical company Otsuka.

Viking Therapeutics also said that its injectable obesity treatment candidate maintained its effectiveness after switching from weekly administration to use once every two weeks or once a month in a phase two trial.